Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19

April 27, 2021 0 Comments

Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-IIa, randomized, double-blinded, placebo controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19.  Our Investigational New Drug (IND) application  will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy in patients with moderate to severe COVID-19. 

Read More

Vitro Biopharma Retains Leading Health Care Executive as Acting  Director of Regulatory Affairs & Director

Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director

April 06, 2021 0 Comments

Vitro Biopharma, Inc. (formerly Vitro Diagnostics, Inc.)  announced the appointment of Dr. Caroline Mosessian, PhD, DRSc, FACMPE, ACHE as its  acting Director of Regulatory Affairs. Dr. Mosessian has an extensive background in regulatory  science including a PhD, MS and Masters in Healthcare Administration degrees from USC in  LA.

Read More

Vitro Biopharma CEO Jack Zamora

Vitro Biopharma Names World Renowned Physician Entrepreneur as its CEO

December 11, 2020 0 Comments

Golden, Colorado-December 10th, 2020-Vitro Diagnostics, Inc., dba Vitro Biopharma announced the appointment by its Board of Directors of Jack Zamora, MD as its new Chief Executive Officer (“CEO”) and the retention of Dr. James Musick, the current CEO as Chief Science Officer (“CSO”).  Dr. Zamora adds new dimensions to Vitro Biopharma’s senior management team.

Read More


Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells®

Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells®

September 21, 2020 0 Comments

Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, jointly with GIOSTAR – a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science – announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®.

Read More

Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells

Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells

September 21, 2020 0 Comments

Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro entered into an exclusive Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, Inc. (“GIOSTAR”) a leading stem cell research institute based in San Diego, California to jointly partner together for a COVID-19 Investigational New Drug 

Read More

Vitro Biopharma Submits IND Application to FDA for AlloRx Stem Cell(R) Therapy of COVID-19

Vitro Biopharma Submits IND Application to FDA for AlloRx Stem Cell(R) Therapy of COVID-19

September 21, 2020 0 Comments

Dr. Jim Musick, Ph.D., CEO said, “We are very pleased to have submitted our IND using our expanded regulatory team, including a renown regulatory expert in FDA clinical trial management. We are establishing strong communication channels with FDA officials to facilitate and expedite review of our application as well as subsequent steps to gain full FDA approval of AlloRx Stem Cells®. 

Read More


Vitro Biopharma Announces MaloneBailey L.L.P. As Its New Auditors

Vitro Biopharma Announces MaloneBailey L.L.P. As Its New Auditors

September 21, 2020 0 Comments

Golden, Colorado-July20th, 2020-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that it has engaged MaloneBailey L.L.P. (Certified Public Accounting Firm www.malonebailey.com ) as its new auditors that will be auditing the company’s consolidated balance sheets as of October 31, 2019 and October 31, 2020,

Read More